August 2012

FDA Approves NUCYNTA ER Extended Release Oral Tablets

Janssen Pharmaceuticals, Inc. announced the FDA has approved the supplemental New Drug Application for NUCYNTA ER extended-release tables for the management of neuropathic pain associated with diabetic peripheral neuropathy. NUCYNTA ER is the first and only opioid approved by the FDA for this purpose. “Pain from DPN can be difficult to manage, leaving some patients …

FDA Approves NUCYNTA ER Extended Release Oral Tablets Read More »

Diabetic Nerve Pain More Common Than Doctors Think

The American Chronic Pain Society joined with Pfizer to conduct a survey on the prevalence of symptoms of diabetic peripheral neuropathy in patients with diabetes. Their results show that nerve pain is reported in about twice as many patients as estimated by healthcare providers. Additionally, the survey found gaps in communication between doctors, nurses, and …

Diabetic Nerve Pain More Common Than Doctors Think Read More »

Acetyl-l-Carnitine Yield Mixed Results for Chemo-Induced Neuropathy

Two clinical trials, one in the US and one in China have been completed on the results of taking Acetyl-l-Carnitine, either during chemotherapy treatments or before treatment. With very different results presented at the American Society of Clinical Oncology annual meeting, there is no clear direction on the use of ALC. Debra Barton, PhD, Mayo Clinic, commented, “Further …

Acetyl-l-Carnitine Yield Mixed Results for Chemo-Induced Neuropathy Read More »

Omega-3 Fatty Acids are Protective Against Paclitaxel-induced Peripheral Neuropathy

First published online by BioMed Central, researchers from Tehran and Tabriz Universities, Iran, have found that Omega-3 fatty acids have beneficial effects on neurological disorders from the side effects of paclitaxel, used to treat breast cancer. Omega-3 fatty acids may be an efficient neuroprotective agent against paclitaxel-induced PN.  READ MORE Source: Equities.com